Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
5 reasons to wear a mask even after you’re vaccinated

5 reasons to wear a mask even after you’re vaccinated

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

New cell therapy can boost immunotherapy against breast cancer

New cell therapy can boost immunotherapy against breast cancer

COVID-19 pandemic highlights the risk of using systemic corticosteroids

COVID-19 pandemic highlights the risk of using systemic corticosteroids

Study shows benefits of integrated palliative and oncology care for patients with advanced AML

Study shows benefits of integrated palliative and oncology care for patients with advanced AML

Researchers discover cells responsible for resistance to T-ALL treatment

Researchers discover cells responsible for resistance to T-ALL treatment

New class of targeted cancer drugs may prove effective in treating common types of leukemia

New class of targeted cancer drugs may prove effective in treating common types of leukemia

Pulmonary hypertension drug may become a treatment option for cancer

Pulmonary hypertension drug may become a treatment option for cancer

New analysis method could pave the way for important breakthroughs in immunotherapy

New analysis method could pave the way for important breakthroughs in immunotherapy

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Study reveals low detection of SARS-CoV-2 on environmental surfaces across oncology settings

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.